An inter partes review is a formal proceeding at the U.S. Patent Office where a third party asks a panel to re-examine and possibly cancel all or part of an issued patent based on earlier public information. Investors care because the outcome can remove or uphold a company’s exclusive rights, directly affecting product exclusivity, potential revenue, legal exposure and the valuation of businesses that rely on that patent—like asking a neutral referee to re-check a key call in a game.
ipRregulatory
IPR stands for intellectual property rights, the legal protections for creations such as inventions, brand names, designs, software and trade secrets. For investors, IPR matters because it can act like a lock or fence around a company’s valuable ideas, creating exclusive income through sales or licensing, reducing competition, and helping determine a firm’s long-term earning power and valuation.
u.s. patent trial and appeal boardregulatory
A U.S. Patent Trial and Appeal Board is a government body that reviews and decides disputes over the validity and scope of patents issued in the United States. For investors it matters because the board can uphold or cancel key patents that protect a company’s products or revenue streams—think of it as a referee who can take away or confirm a team’s exclusive rights, which can quickly change a company’s competitive position and valuation.
ptabregulatory
The PTAB is the Patent Trial and Appeal Board, a U.S. administrative body that reviews and decides challenges to the validity of issued patents—think of it as a referee or appeals court for patent rights. Its decisions can remove or confirm legal protections that give companies exclusive control over products or technologies, which matters to investors because those outcomes can sharply change a company’s future revenue prospects, competitive position, and legal risk.
u.s. patent no. 11,435,360regulatory
U.S. Patent No. 11,435,360 is a unique identifier for a specific patent granted by the United States Patent and Trademark Office; it represents a legal right to exclude others from making, using, selling or importing the patented invention in the U.S. For investors, a granted patent is like a deed to intellectual property: it can create a competitive moat, enable licensing revenue, and change a company’s value or risk profile by protecting products or technologies from copycats.
usptoregulatory
United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.
nanoparticlemedical
A nanoparticle is an extremely tiny particle—often a thousand times smaller than the width of a human hair—measured at the scale of billionths of a meter. They act like microscopic packets or building blocks used to carry drugs, enhance materials, or enable new sensors, and their unique size can change how a product works or how regulators view its safety. Investors watch nanoparticle use because it can drive product advantage, regulatory scrutiny, manufacturing cost changes, and market potential.
proteomicsmedical
Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
US PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360
SCHLIEREN, Switzerland & MUNICH--(BUSINESS WIRE)--
PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR2024‑01473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women’s Hospital, and exclusively licensed to Seer, Inc.
The USPTO struck down the sole independent claim of the ‘360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic range.
“This outcome confirms what we have consistently believed from the outset: the fundamental concepts at issue were already known in the scientific literature,” said Dr. Oliver Rinner, co-founder and managing director of Biognosys AG. “We welcome the PTAB’s thorough evaluation and we are very pleased with this clear result.”
PreOmics and Biognosys remain committed to advancing high‑performance sample preparation and software for proteomics and multiomics workflows for researchers worldwide.
About Biognosys and PreOmics
Biognosys and PreOmics are part of the Biognosys Group that delivers high-performance, robust solutions across proteomics, metabolomics, and lipidomics — driving innovation at the forefront of multiomics. Building on the combined strengths of PreOmics, Biognosys, and biocrates, Biognosys Group integrates industry-leading consumables, software, instruments, and CRO services to make advanced mass spectrometry workflows seamless, scalable, and accessible to every laboratory. The Biognosys Group maintains a vendor-neutral strategy, ensuring open and flexible collaboration across the scientific community and broad compatibility of its solutions across the major mass spectrometry platforms. Designed for agility, our technologies can operate independently or within a unified ecosystem, supported by flexible business models and a strong commitment to partnership. PreOmics GmbH and Biognosys AG are subsidiaries of Bruker Corporation (Nasdaq: BRKR).
